Literature DB >> 11389011

Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease.

M C Dinauer1, M A Gifford, N Pech, L L Li, P Emshwiller.   

Abstract

Chronic granulomatous disease (CGD) is an inherited immunodeficiency in which the absence of the phagocyte superoxide-generating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase results in recurrent bacterial and fungal infections. A murine model of X-linked CGD (X-CGD) was used to explore variables influencing reconstitution of host defense following bone marrow transplantation and retroviral-mediated gene transfer. The outcomes of experimental infection with Aspergillus fumigatus, Staphylococcus aureus, or Burkholderia cepacia were compared in wild-type, X-CGD mice, and transplanted X-CGD mice that were chimeric for either wild-type neutrophils or neutrophils with partial correction of NADPH oxidase activity after retroviral-mediated gene transfer. Host defense to these pathogens was improved in X-CGD mice even with correction of a limited number of neutrophils. However, intact protection against bacterial pathogens required relatively greater numbers of oxidant-generating phagocytes compared to protection against A fumigatus. The host response also appeared to be influenced by the relative level of cellular NADPH oxidase activity, particularly for A fumigatus. These results may have implications for developing effective approaches for gene therapy of CGD. (Blood. 2001;97:3738-3745)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389011     DOI: 10.1182/blood.v97.12.3738

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice.

Authors:  Xingkui Xue; Nancy K Pech; W Christopher Shelley; Edward F Srour; Mervin C Yoder; Mary C Dinauer
Journal:  Blood       Date:  2010-09-02       Impact factor: 22.113

Review 2.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

3.  CRISPR-Mediated Knockout of Cybb in NSG Mice Establishes a Model of Chronic Granulomatous Disease for Human Stem-Cell Gene Therapy Transplants.

Authors:  Colin L Sweeney; Uimook Choi; Chengyu Liu; Sherry Koontz; Seung-Kwon Ha; Harry L Malech
Journal:  Hum Gene Ther       Date:  2017-03-06       Impact factor: 5.695

4.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.

Authors:  Giorgia Santilli; Elena Almarza; Christian Brendel; Uimook Choi; Chiara Beilin; Michael P Blundell; Sneha Haria; Kathryn L Parsley; Christine Kinnon; Harry L Malech; Juan A Bueren; Manuel Grez; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

Review 5.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 6.  Gene therapy of chronic granulomatous disease: the engraftment dilemma.

Authors:  Manuel Grez; Janine Reichenbach; Joachim Schwäble; Reinhard Seger; Mary C Dinauer; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

7.  Burkholderia cenocepacia creates an intramacrophage replication niche in zebrafish embryos, followed by bacterial dissemination and establishment of systemic infection.

Authors:  Annette C Vergunst; Annemarie H Meijer; Stephen A Renshaw; David O'Callaghan
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

8.  Mitochondrial transmembrane potential is diminished in phorbol myristate acetate-stimulated peritoneal resident macrophages isolated from wild-type mice, but not in those from gp91-phox-deficient mice.

Authors:  Toshihiro Kobayashi; Yasuhiro Ogawa; Yoshiya Watanabe; Masato Furuya; Sayo Kataoka; Eva Garcia del Saz; Shohko Tsunawaki; Mary C Dinauer; Harumichi Seguchi
Journal:  Histochem Cell Biol       Date:  2004-07-09       Impact factor: 4.304

9.  Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Authors:  Christian Brendel; Walther Hänseler; Vital Wohlgensinger; Matteo Bianchi; Serap Tokmak; Linping Chen-Wichmann; Elena Kuzmenko; Nikola Cesarovic; Flora Nicholls; Janine Reichenbach; Reinhard Seger; Manuel Grez; Ulrich Siler
Journal:  Hum Gene Ther Methods       Date:  2013-05-02       Impact factor: 2.396

10.  Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.

Authors:  Giada Farinelli; Raisa Jofra Hernandez; Alice Rossi; Serena Ranucci; Francesca Sanvito; Maddalena Migliavacca; Chiara Brombin; Aleksandar Pramov; Clelia Di Serio; Chiara Bovolenta; Bernhard Gentner; Alessandra Bragonzi; Alessandro Aiuti
Journal:  Mol Ther       Date:  2016-07-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.